AMAALA
24.6.2020 18:13:08 CEST | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coast, has unveiled plans for a new international airport, with a design inspired by the optical illusion of a desert mirage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005664/en/
The terminal and control tower design was conceptualised by UK-based architectural and design firm Foster + Partners, while the airport master plan was designed by Egis, an international consultancy and engineering group. It will incorporate unique design practices, drawing inspiration from its location. The airport is due for completion in 2023 and is estimated to accommodate one million travellers per year once it officially opens.
Commenting on the announcement of the new international airport, the Chief Executive Officer of AMAALA, Nicholas Naples, said: “A gateway to AMAALA, visitors will be greeted by personalised experiences from the moment they step off the plane. From design to personalisation, this will be no ordinary airport. Immersed in the spirit of AMAALA, the airport will create an environment that embodies the philosophy of the destination beyond. This will be a unique space that personifies luxury and marks the start of memorable experiences for the world’s most discerning guests. We are delighted to work with Foster + Partners and Egis on this project.”
On approaching the airport, travellers will see stunning land art from the air. Entering the terminal, visitors will be greeted with a sleek mirrored edifice rising from the desert. The structure takes its inspiration from the surrounding environment, resulting in a mesmerising mirage effect. A spacious courtyard will anchor the terminal and will be complemented by contemporary interiors complete with unique artwork and tailored experiences. The airport will reflect AMAALA’s ultra-luxury hospitality spirit, providing an exclusive private-club experience perfectly encapsulating AMAALA’s pillars of art and culture; wellness and sport; and sea, sun, and lifestyle.
Among the list of amenities provided by the airport are climate-controlled hangars that will be available for private jets as well as a ground transfer service that is accessible from inside the arrival hangar.
Senior Executive Partner of Foster + Partners, Gerard Evenden, said, “Responding to the surrounding landscape, the terminal building will form an exclusive gateway to the AMAALA resort. The passenger experience through the entire building will be akin to a private members club – luxurious and relaxing. Focusing on the themes of art, wellbeing and sport, the design seeks to establish a new model for private terminals that provides a seamless experience from resort to aeroplane.”
Middle East & South Asia Aviation Director of Egis, Jacques Khoriaty , said: “Along with embodying the luxurious spirit of the resort, the AMAALA airport meets the highest environmental design and sustainability standards, is operationally versatile and incorporates the latest airport technology and best practice standards on offer. It has been a privilege to have worked closely with AMAALA to define the requirements of this unique project and we look forward continuing our support all the way through to the opening of the airport in 2023.”
For the airport video rendering, please visit here .
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005664/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom